Observing Platelet Activability in a Once daily vs. a More frequent Aspirin intake regime

Completed

• Conditions: Myocardial infarction Heart attack; 10011082

• Registration Number: NL-OMON42162
• Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary

Trial is onging in other countries

Detailed Description

Not available

Study Timeline

• Study Completion: 2019-01-03
• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 35

Inclusion Criteria

- Outpatients being treated for stable cardiovascular disease by the cardiology department.
- Stable cardiovascular disease defined as: coronary artery disease, peripheral vascular disease or previous myocardial infarction.
- Intake of 80 mg of acetylsalicylic acid once a day

Exclusion Criteria

- Active bleeding
- Diabetes mellitus
- Thrombocytopenia
- Thrombocytosis
- Valvualar heart disease/dysfunction
- Thrombopathy (e.g. von Willebrand disease, Glanzmann*s thrombasthenia and Bernard-Soulier syndrome) ;
- Any ischemic event or revascularization procedure (percutaneous coronary intervention or coronary artery bypass grafting) within the last six months;
- Alcohol intake the day before blood sampling;
- Non-compliance to the protocol ;
- Baxter rolls (i.e. presorted medicine by a pharmacist) ;
- Recent use of antiplatelet drugs, anticoagulants or drugs that are known to alter platelet function, other than aspirin (e.g. NSAID*s, tirofiban, eptifibatide, abciximab, beta-lactam antibiotics, dextran, SSRI*s, clomipramine & amitriptyline, dipyridamole, verapamil, diltiazem , ginkgo biloba, ginseng, St John*s wort). ;

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>We will analyze whether a twice daily regimen is superior to a once daily<br /><br>regime of aspirin when it comes to inhibiting platelet aggregation in<br /><br>cardiovascular patients, as measured by the PFA-200, Chrono-log light<br /><br>transmission aggregometry, VerifyNow, and a TBX2 serum ELISA. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Platelet- , reticulated platelet- , leucocyte count and haemoglobin level as a<br /><br>possible effect modifying parameter.</p><br>